[Press release] Atea Pharmaceuticals initiates first-in-human Phase 1 clinical trial of AT-587 for the treatment of hepatitis E virus

Atea Pharmaceuticals press release

Atea Pharmaceuticals, Inc. announced the initiation of a first-in-human Phase 1 clinical trial evaluating AT-587, for the treatment of hepatitis E virus (HEV) infection.

AT-587 is a proprietary oral antiviral nucleotide analog being developed for the treatment of HEV, a potentially serious liver disease that can lead to chronic infection, cirrhosis and liver failure in certain patient populations.

The Phase 1 trial is a randomized, double-blind, placebo-controlled, sequential dose-escalation study designed to evaluate the safety, tolerability and pharmacokinetics of AT-587 in healthy volunteers. The study includes both single ascending dose and multiple ascending dose components, as well as an embedded food-effect assessment.

Read the full press release here.

Source : Atea Pharmaceuticals, Inc.